ZGGS34 / Suzhou Zelgen - LARVOL DELTA

First-in-human Phase I/II Study of ZGGS34, a Trispecific anti-T cell Engager (Tri-TCE) Targeting MUC17/CD3/CD28, as Monotherapy in Patients with Advanced Solid Tumors (ESMO 2026) - No abstract available

Clinical • First-in-human • Metastases • Monotherapy • P1/2 data • Trispecific • Oncology • Solid Tumor • MUC17

Study of ZGGS34 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=400 | Recruiting | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Cancer • Gastric Cancer • Oncology • Solid Tumor • HER-2 • MSI • MUC17

Study of ZGGS34 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=400 | Not yet recruiting | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

New P1/2 trial • Solid Tumor

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA) has approved its clinical trial of ZGGS34 for Injection (flcube.com) - "The drug, a trispecific T‑cell engager (TriTE) that simultaneously binds CD3, CD28, and the tumor‑associated antigen MUC17, is slated for use in patients with MUC17‑positive advanced solid tumors....Suzhou Zelgen plans to initiate the first‑in‑human Phase II study later this year, enrolling up to 120 MUC17‑positive patients across 10 sites nationwide."

New P2 trial • Solid Tumor